Market News & Trends
Apollomics Announces Updated Strategic Focus & Leadership Team Changes
Apollomics Inc. recently announced an updated strategic focus for the clinical development of vebreltinib by focusing on NSCLC patients with Met Amplification, as well as…
Sobi Initiates Rolling BLA to FDA for SEL-212 for the Potential Treatment of Chronic Refractory Gout
Sobi recently announced the initiation of a rolling Biologics License Application (BLA) to the USA FDA for SEL-212. The submission is based on the results…
Cellular Origins Acquires ACTIA Platform IP to Enhance Automated Cell Therapy Manufacturing
Cellular Origins recently announced the acquisition of the ACTIA (Autologous Cell Therapy Industrial Automation) Platform IP, developed by Geoff Hodge whilst CEO of SOTIO Biotech…
Cartesian Therapeutics Announces Positive Topline Results from Phase 2b Trial of Descartes-08 in Patients With Myasthenia Gravis
Cartesian Therapeutics, Inc. recently announced positive topline results from its Phase 2b trial of Descartes-08 in patients with generalized myasthenia gravis (MG). Descartes-08, Cartesian’s lead…
Annovis Bio Announces New Data From Phase 3 Parkinson’s Study
Annovis Bio Inc. recently announced new data from its Phase 3 PD study demonstrating that buntanetap is safe and effective in improving motor and non-motor…
Inozyme Pharma Announces FDA Fast Track Designation for INZ-701 in ABCC6 Deficiency
Inozyme Pharma, Inc. recently announced the US FDA has granted Fast Track designation to INZ-701 for the treatment of ABCC6 Deficiency. “Through Fast Track designation,…
Alvotech Announces Positive Topline Results for a Proposed Biosimilar for Prolia & Xgeva
Alvotech recently announced positive topline results from a confirmatory patient study for AVT03, a proposed biosimilar to Prolia (denosumab) and Xgeva (denosumab). The study met…
Touchlight & LenioBio Collaborate to Accelerate Development of Protein Therapeutics for Pandemic Response
LenioBio and Touchlight recently announced a supply agreement aimed at leveraging the revolutionary capabilities of Touchlight’s rapid enzymatic doggybone DNA (dbDNA) to achieve unprecedented speed…
Navin Molecular to Invest Up to $35 Million to Expand GMP Manufacturing Capabilities
Navin Molecular recently announced a $35-million investment to construct a 9,000-square-meter GMP manufacturing plant in Dewas, India. The new facility will nearly double overall capacity…
Ovid Therapeutics & Graviton Bioscience Announce Topline Data From Phase 1 Clinical Trial Studying a Potential First-In-Class Therapy for Cerebral Cavernous Malformations
Ovid Therapeutics Inc. and Graviton Bioscience Corporation recently announced the results from their Phase 1 healthy volunteer study evaluating the safety, tolerability, and pharmacokinetic (PK)…
Biora Therapeutics Announces Positive Clinical Trial Results for BT-600
Biora Therapeutics, Inc. recently shared positive topline results from its clinical trial of BT-600, an orally administered drug-device combination in development for the potential treatment…
Syncromune Granted FDA Fast-Track Designation for the Treatment of Metastatic Castrate-Resistant Prostate Cancer
Syncromune Inc. recently announced the US FDA has granted Fast Track designation for SYNC-T SV-102 therapy, its lead candidate for the treatment of patients with metastatic…
Artelo Biosciences Presents Preclinical Data on ART26.12 in Breast Cancer-Induced Bone Pain
Artelo Biosciences, Inc. recently announced Professor Saoirse O’Sullivan, Vice President of Translational Sciences at Artelo, presented preclinical data related to ART26.12, Artelo’s novel fatty acid binding…
NeOnc Technologies Completes $18.5-Million Financing, Advances Phase 2 Clinical Trials for Enhanced Method of Delivering Novel Therapeutics to the Brain Under FDA Fast-Track Status
NeOnc Technologies Holdings, Inc. has completed an $18.5-million financing to support the ongoing development and Phase 1 and 2 clinical studies of its novel drug…
Nxera Pharma Receives $10 Million From AbbVie as Collaboration Targeting Neurological Diseases Achieves First R&D Milestone
Nxera Pharma Co. Ltd recently announced it has reached an important R&D milestone under its multi-target discovery collaboration with AbbVie targeting neurological diseases, resulting in…
GRI Bio Announces Patent Granted for Proprietary Natural Killer T Cell Modulators
GRI Bio, Inc. recently announced the Korean Intellectual Property Office (KIPO) has granted Patent No. 10-2665487 titled Prevention and Treatment of Inflammatory Conditions. The granted…
Inmagene Announces Positive Topline Results of a Multiple Ascending Dose Study of a Non-Covalent Reversible BTK Inhibitor With Once- Daily Dosing Potential
Inmagene Biopharmaceuticals recently announced positive topline results from the multiple ascending dose (MAD) portion of its randomized, double-blind, placebo-controlled Phase 1 study of IMG-004, a…
Veranova Announces New Investment to Expand ADC & Highly Potent API Capabilities at MA Facility
Veranova recently announced initiation of a significant expansion of its antibody-drug conjugate (ADC) and highly potent compound development and manufacturing capabilities at its Devens, MA,…
GT Biopharma Announces FDA Clearance of IND Application for NK Cell Engager for Treatment of CD33+ Leukemia
GT Biopharma, Inc. recently announced FDA clearance of its IND application for GTB-3650, allowing the company to proceed with a Phase 1 clinical trial, which is…
Agile Therapeutics Announces Definitive Merger Agreement With Insud Pharma
Agile Therapeutics, Inc. recently announced it has entered into a definitive merger agreement with Insud Pharma, S.L. pursuant to which Insud, through its US subsidiary,…
